Understanding sensitivity and resistance to BRAF inhibitors in melanoma

Funded Activity Summary

Recent clinical studies have shown that the most common mutation found in melanoma in the gene BRAF can be successfully targeted for treatment. However many patient relapse after early responses and the drug can also cause growth of some skin tumours. This proposal will investigate the reasons for these observations using molecular-imaging and study of tumour tissues and cell lines. This will lead to new insights and better treatments for melanoma and other cancers with BRAF gene mutations.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $484,746.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer | cancer chemotherapy | drug development | melanoma | metabolism | molecular imaging | oncogenes | translational research

Related Links